A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

Chemotherapy Induced Anemia Clinical Trial

Official title:
A Multicenter, Open-Label Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the effectiveness and safety of recombinant human erythropoietin in anemic cancer patients undergoing chemotherapy.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Chemotherapy Induced Anemia

Clinical Trial Details

NCT number	NCT00144495
Study type	Interventional
Source	Chugai Pharmaceutical
Contact
Status	Completed
Phase	Phase 3
Start date	February 2004
Completion date	May 2005

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05301517` - A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies	Phase 3
Terminated	`NCT00931606` - Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012)	Phase 2
Completed	`NCT00272662` - Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy	Phase 2
Not yet recruiting	`NCT06075030` - A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy	Phase 2
Completed	`NCT00144482` - A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy	Phase 3
Completed	`NCT04076943` - Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia	Phase 2